Valeo Pharma, Inc. engages in the acquisition and in-licensing of branded pharmaceutical and hospital specialty products for sale. The company is headquartered in Kirkland, Quebec and currently employs 70 full-time employees. The firm acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The firm is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The firm's wholly owned subsidiary is VPI Pharmaceuticals Inc.
